Caricamento...
Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with a poor prognosis is usually detected at the advanced stage of the disease. The only US Food and Drug Administration-approved biomarker that is available for PDAC, CA 19-9, is most useful in monitoring treatment response amo...
Autori principali: | , , , , , |
---|---|
Natura: | Online Articolo testo |
Lingua: | English |
Pubblicazione: |
MDPI
2022
|
Soggetti: | |
Accesso online: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879036/ https://www.ncbi.nlm.nih.gov/pubmed/35216204 http://dx.doi.org/10.3390/ijms23042093 |